(Q50920040)

25 March 2018

title

Advanced prostate cancer--a case for adjuvant differentiation therapy. (English)

1 reference

25 March 2018

author

Norman Maitland

series ordinal

3

1 reference

25 March 2018

author name string

Jayant K Rane

series ordinal

1

1 reference

25 March 2018

Davide Pellacani

series ordinal

2

1 reference

25 March 2018

language of work or name

English

0 references

publication date

14 August 2012

1 reference

25 March 2018

published in

Nature Reviews Urology

1 reference

25 March 2018

volume

9

1 reference

25 March 2018

issue

10

1 reference

25 March 2018

page(s)

595-602

1 reference

25 March 2018

https://scigraph.springernature.com/pub.10.1038/nrurol.2012.157

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The changing therapeutic landscape of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

New therapies for castration-resistant prostate cancer: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Embryonic stem cell markers expression in cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prospective identification of tumorigenic prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The cancer stem cell: premises, promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The therapeutic promise of the cancer stem cell concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Cancer stem cells: problems for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prostate cancer stem cells: do they have a basal or luminal phenotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prostate cancer stem cells: are they androgen-responsive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Expression of basal cell keratins in human prostate cancer metastases and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prostate epithelial stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Reversing breast cancer stem cell into breast somatic stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Unique features of the basal cells of human prostate epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Diagnosis of adenocarcinoma in prostate needle biopsy tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The impact of low-dose busulfan on clonal dynamics in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Stem cell origin of cancer and differentiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Differentiation therapy of leukemia: 3 decades of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Vitamin D metabolism and action in the prostate: implications for health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Natural and synthetic retinoids in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Mycophenolic acid-induced replication arrest, differentiation markers and cell death of androgen-independent prostate cancer cells DU145.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Differentiating agents and the treatment of prostate cancer: Vitamin D3 and peroxisome proliferator-activated receptor gamma ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Perifosine induces differentiation and cell death in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Direct observation of a free radical interaction between vitamin E and vitamin C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

CD133, a novel marker for human prostatic epithelial stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Basal epithelial stem cells are efficient targets for prostate cancer initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Expression profiling of CD133+ and CD133- epithelial cells from human prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Abiraterone in prostate cancer: a new angle to an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.157

Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells

31 March 2020

1 reference

12 December 2020

Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion

1 reference

12 December 2020

Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines

1 reference

12 December 2020

Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation

1 reference

12 December 2020

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

1 reference

12 December 2020

The effects of telomerase inhibition on prostate tumor-initiating cells

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

12 December 2020

Cytokeratin characterization of human prostatic carcinoma and its derived cell lines.

1 reference

12 December 2020

Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

1 reference

12 December 2020

Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathway

1 reference

12 December 2020

Cancer stem cells - A therapeutic target?

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2012.157

1 reference

25 March 2018

release_37o77a4ifvgihovuydxfbvksku

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/37o77a4ifvgihovuydxfbvksku

24 November 2022

mapped directly with Wikidata item

1 reference

25 March 2018